# Local Therapeutic Strategies for Neurocutaneous Dysesthesia: From Capsaicin to Cannabinoids > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/local-therapeutic-strategies-neurocutaneous-dysesthesia/ > **Published:** 2026-03-26T15:05:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:37:24-04:00 > **Clinical Summary:** Explore local therapeutic strategies neurocutaneous dysesthesia including capsaicin and cannabinoids for targeted topical treatment options. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic [Neuropathic Pain](https://cedclinic.com/cannabis-for-pain-relief/)Topical TherapyCannabinoidsDermatology[Pain Management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) Journal The Journal of dermatological treatment Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters Neurocutaneous dysesthesia affects [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) significantly, yet lacks standardized treatment protocols. This comprehensive review of topical therapies provides clinicians with evidence-based local treatment options, particularly valuable when systemic medications are contraindicated or as first-line therapy for localized symptoms. Clinical Summary This narrative review systematically evaluates topical treatment modalities for neurocutaneous dysesthesia, a condition characterized by abnormal skin sensations without underlying dermatologic pathology. The authors examine mechanisms of action for various topical agents including capsaicin, calcineurin inhibitors, local anesthetics, tricyclic antidepressants, anticonvulsants, and cannabinoids. The review addresses a significant gap in clinical guidance for this challenging condition where treatment approaches have been largely empirical. While comprehensive in scope, the review’s clinical utility is limited by the absence of comparative effectiveness data and standardized dosing protocols for most agents discussed. Dr. Caplan’s Take “This review fills an important clinical gap by organizing scattered evidence on topical treatments for neuropathic skin conditions. However, the inclusion of cannabinoids appears somewhat superficial without detailed discussion of specific formulations, dosing strategies, or clinical trial data that would guide practical implementation.” Clinical Perspective 🧠 Clinicians should consider topical therapies as first-line treatment for localized neurocutaneous dysesthesia, particularly in elderly patients or those with contraindications to systemic medications. The step-wise approach suggested here provides a rational framework, though individual agent selection should be guided by symptom characteristics and patient tolerance rather than rigid protocols. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Local%20therapeutic%20strategies%20for%20neurocutaneous%20dysesthesia%3A%20from%20capsaicin%20to%20c...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41884965/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41884965/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Local%20therapeutic%20strategies%20for%20neurocutaneous%20dysesthesia%3A%20from%20capsaicin%20to%20c...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41884965/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41884965/](https://pubmed.ncbi.nlm.nih.gov/41884965/) Table of Contents - [FAQ](#FAQ)[What is neurocutaneous dysesthesia and how does it present clinically?](#What_is_neurocutaneous_dysesthesia_and_how_does_it_present_clinically) - [Why should clinicians consider topical treatments as first-line therapy for neurocutaneous dysesthesia?](#Why_should_clinicians_consider_topical_treatments_as_first-line_therapy_for_neurocutaneous_dysesthesia) - [What evidence exists for cannabinoid use in treating neurocutaneous dysesthesia?](#What_evidence_exists_for_cannabinoid_use_in_treating_neurocutaneous_dysesthesia) - [How do topical treatments for neurocutaneous dysesthesia work mechanistically?](#How_do_topical_treatments_for_neurocutaneous_dysesthesia_work_mechanistically) - [What clinical approach should be taken when treating neurocutaneous dysesthesia?](#What_clinical_approach_should_be_taken_when_treating_neurocutaneous_dysesthesia) - [Related](#Related) ## FAQ #### What is neurocutaneous dysesthesia and how does it present clinically? Neurocutaneous dysesthesia (ND) is a condition characterized by abnormal skin sensations such as burning, itching, or pruritus without any underlying visible skin pathology. It results from nerve damage or compression affecting somatosensory pathways, with symptoms varying greatly in location and extent depending on which nerve sites are affected. #### Why should clinicians consider topical treatments as first-line therapy for neurocutaneous dysesthesia? Local topical therapy offers a valuable first-step treatment approach, particularly for mild cases or when systemic medications are contraindicated due to [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) or drug interactions. Topical treatments can provide targeted relief with reduced systemic exposure and potentially fewer adverse effects compared to oral medications. #### What evidence exists for cannabinoid use in treating neurocutaneous dysesthesia? This review identifies cannabinoids as one of the available local treatment modalities for ND, though specific efficacy data and mechanisms of action would require examination of the complete study details. The evidence is currently categorized as “monitored relevance,” indicating it represents an early-stage signal requiring further research before clinical implementation. #### How do topical treatments for neurocutaneous dysesthesia work mechanistically? The review describes various mechanisms of action for different topical agents, including capsaicin (TRPV1 receptor modulation), calcineurin inhibitors (immune modulation), local anesthetics like lidocaine (sodium channel blockade), and other agents targeting specific pain pathways. Each treatment option works through distinct molecular mechanisms to address the abnormal sensory signaling characteristic of ND. #### What clinical approach should be taken when treating neurocutaneous dysesthesia? Treatment of ND is challenging due to the lack of established step-by-step clinical guidelines and the variable presentation of symptoms. A rational approach involves starting with topical therapies, particularly for localized or mild symptoms, before considering systemic treatments, though individualized treatment selection should be based on symptom severity, location, and patient-specific factors. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41884965/”, “about”: “journal dermatological treatment [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) local”, “isPartOf”: “The Journal of dermatological treatment”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) Explore clinical evidence and formulation strategies for cannabinoid therapies in less-common disorders relevant to neurocutaneous dysesthesia. [Read More](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) [Results of an Exploratory Crossover Pharmacokinetic Study Evaluating a Natural Hemp Extract-Based Cosmetic Product.](https://cedclinic.com/topical-hemp-pharmacokinetics-study-systemic-absorption/) Compare topical and oral routes of administration for hemp extract-based products, relevant for local therapeutic strategies. [Explore Study](https://cedclinic.com/topical-hemp-pharmacokinetics-study-systemic-absorption/) [Lifestyle and Behavioral Enhancements of Sleep: A Review.](https://cedclinic.com/sleep-hygiene-cbt-i-lifestyle-enhancements/) Review lifestyle and behavioral strategies that may complement local therapies for neurocutaneous dysesthesia symptom management. [Learn More](https://cedclinic.com/sleep-hygiene-cbt-i-lifestyle-enhancements/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).